Breaking News Instant updates and real-time market news.

SPHS

Sophiris Bio

$2.74

0.13 (4.98%)

18:37
08/14/18
08/14
18:37
08/14/18
18:37

Sophiris Bio topsalycin trial death disclosure imminent, says Piper Jaffray

Piper Jaffray analyst Christopher Raymond kept his Overweight rating and $7 price target on Sophiris Bio after its "uneventful" Q2 report. The analyst says that while the company did not update on the cause of death of one of its Phase 2b topsalycin trial patients, conversations with the management suggest that the disclosure is "imminent". Raymond adds that with the cause of death being announced, the "cloud" over the program will be lifted, allowing investors to focus on the drug's "impressive efficacy".

SPHS Sophiris Bio
$2.74

0.13 (4.98%)

06/26/18
PIPR
06/26/18
NO CHANGE
Target $7
PIPR
Overweight
Sophiris Bio 'worth sticking with' after patient death, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond maintained an Overweight rating and $7 price target on Sophiris Bio following disclosure of Phase 2b topsalysin data in localized prostate cancer. In a research note to investors, Raymond contended that while a patient death is "never a great headline," and that death after retreatment has now placed a cloud over the program, he thinks there is a good chance this incident may end up not being categorized as drug-related, and thinks it's worth "sticking with it here." Raymond sees a "credible" path forward with single administration, and urges investors to be patient on the name as clarity on the death and clinical path come more into focus.
06/25/18
PIPR
06/25/18
NO CHANGE
Target $7
PIPR
Overweight
Piper says Sophiris Bio 'worth sticking with' despite patient death in trial
A patient death after retreatment has "placed a cloud" over Sophiris Bio's topsalysin program despite efficacy data that was "clearly a home run," according to Piper Jaffray analyst Christopher Raymond. He sees a good chance the incident may end up not being categorized as drug-related, noting that topsalysin previously had shown a "pristine safety profile," and Raymond thinks the stock is "worth sticking with" at this point. The analyst, who is reserving judgment until more detail on topsalysin's role in the death is available, thinks there remains a credible path forward even if the death is deemed drug related. He keeps an Overweight rating and $7 price target on Sophiris shares, which fell about 40% to $2.24 today.
06/25/18
MAXM
06/25/18
NO CHANGE
MAXM
Sophiris Bio's topsalysin remains a vaible PC drug candidate, says Maxim
Maxim analyst Jason McCarthy said Buy rated Sophiris Bio shares are being pressured by a patient death, which the cause remains unknown. The analyst said the data for single administration is positive and there have bee no safety issues. McCarthy continues to believe that topsalysin remains a viable PC drug candidate, but notes we have to wait on repeat administration data later in 2018 and a report on the patient.
06/25/18
HCWC
06/25/18
NO CHANGE
Target $4.3
HCWC
Buy
Sophiris Bio price target cut to $4.30 from $6 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis lowered his price target on Sophiris Bio to $4.30 from $6 and maintained a Buy rating on shares after the company announced top-line interim safety and biopsy data following a single administration of topsalysin from its ongoing open-label Phase 2b clinical trial. In a research note to investors, the analyst noted that the study demonstrated that a single administration of topsalysin promoted a clinical response, with 29% of treated patients showing clinical responses at six months of follow up, but added that the company was recently notified that one subject died on the same day after the second administration of topsalysin. The company is currently investigating the cause of death, with no information currently, and no additional patients are receiving a second topsalysin dose. While today's data is "impressive," Pantginis said the patient death has placed a cloud over the story until there is more information, and future scenarios may include a clinical hold on topsalysin by the FDA or the patient death is deemed unrelated to the drug, leading to the study continuing as planned.

TODAY'S FREE FLY STORIES

FII

Federated Investors

$24.65

-0.02 (-0.08%)

21:40
12/16/18
12/16
21:40
12/16/18
21:40
Initiation
Federated Investors initiated  »

Federated Investors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIII

G-III Apparel

$28.68

-0.29 (-1.00%)

21:37
12/16/18
12/16
21:37
12/16/18
21:37
Upgrade
G-III Apparel rating change  »

G-III Apparel upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLXT

Calyxt

$9.88

0.4 (4.22%)

21:34
12/16/18
12/16
21:34
12/16/18
21:34
Upgrade
Calyxt rating change  »

Goldman upgrades Calyxt…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLXT

Calyxt

$9.88

0.4 (4.22%)

20:23
12/16/18
12/16
20:23
12/16/18
20:23
Upgrade
Calyxt rating change  »

Calyxt upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CEQP

Crestwood Equity

$32.29

0.47 (1.48%)

, EQM

EQT Midstream Partners

$46.86

-0.1 (-0.21%)

20:08
12/16/18
12/16
20:08
12/16/18
20:08
Recommendations
Crestwood Equity, EQT Midstream Partners analyst commentary  »

Goldman upgrades…

CEQP

Crestwood Equity

$32.29

0.47 (1.48%)

EQM

EQT Midstream Partners

$46.86

-0.1 (-0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ITW

Illinois Tool Works

$131.02

-2.26 (-1.70%)

19:57
12/16/18
12/16
19:57
12/16/18
19:57
Downgrade
Illinois Tool Works rating change at Deutsche Bank »

Illinois Tool Works…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWK

Stanley Black & Decker

$118.36

0.46 (0.39%)

19:57
12/16/18
12/16
19:57
12/16/18
19:57
Upgrade
Stanley Black & Decker rating change at Deutsche Bank »

Stanley Black &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INCY

Incyte

$66.24

-1.04 (-1.55%)

, AET

Aetna

$0.00

(0.00%)

19:31
12/16/18
12/16
19:31
12/16/18
19:31
Hot Stocks
Fly Intel: Top five weekend stock stories »

Catch up on the…

INCY

Incyte

$66.24

-1.04 (-1.55%)

AET

Aetna

$0.00

(0.00%)

ANTM

Anthem

$275.59

-4.93 (-1.76%)

CNC

Centene

$127.55

-5.3 (-3.99%)

CI

Cigna

$205.34

-6.63 (-3.13%)

HNT

Health Net

$0.00

(0.00%)

HUM

Humana

$300.41

-12.09 (-3.87%)

MOH

Molina Healthcare

$131.72

-11.19 (-7.83%)

UNH

UnitedHealth

$265.06

-7.2 (-2.64%)

WCG

WellCare

$236.90

-7.44 (-3.04%)

SNE

Sony

$51.32

-0.88 (-1.69%)

GOOG

Alphabet

$1,041.68

-21.44 (-2.02%)

GOOGL

Alphabet Class A

$1,050.62

-23.36 (-2.18%)

AAPL

Apple

$165.48

-5.45 (-3.19%)

BAC

Bank of America

$24.49

0.1 (0.41%)

BLK

BlackRock

$382.25

-5.29 (-1.37%)

CAT

Caterpillar

$126.78

0.79 (0.63%)

CVX

Chevron

$113.84

-2.15 (-1.85%)

DDAIF

Daimler AG

$0.00

(0.00%)

DAL

Delta Air Lines

$53.50

-0.03 (-0.06%)

ET

Energy Transfer LP

$14.08

-0.5 (-3.43%)

TOL

Toll Brothers

$32.23

-0.4 (-1.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

  • 10

    Jan

  • 29

    Jan

  • 05

    Feb

  • 12

    Feb

  • 19

    Feb

  • 24

    Feb

  • 03

    Mar

EQT

EQT Corporation

$19.40

-0.78 (-3.87%)

18:54
12/16/18
12/16
18:54
12/16/18
18:54
Periodicals
EQT's board to seek meeting with Rice brothers, Reuters reports »

EQT Corporation's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQM

EQT Midstream Partners

$46.86

-0.1 (-0.21%)

, EQGP

EQGP Holdings

$19.94

0.02 (0.10%)

18:31
12/16/18
12/16
18:31
12/16/18
18:31
Downgrade
EQT Midstream Partners, EQGP Holdings rating change at Goldman Sachs »

EQT Midstream downgraded…

EQM

EQT Midstream Partners

$46.86

-0.1 (-0.21%)

EQGP

EQGP Holdings

$19.94

0.02 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CEQP

Crestwood Equity

$32.29

0.47 (1.48%)

18:28
12/16/18
12/16
18:28
12/16/18
18:28
Upgrade
Crestwood Equity rating change at Goldman Sachs »

Crestwood Equity upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INCY

Incyte

$66.24

-1.04 (-1.55%)

17:52
12/16/18
12/16
17:52
12/16/18
17:52
Hot Stocks
Innovent, Incyte announce agreement for three clinical-stage candidates in China »

Incyte and Innovent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

NSANY

Nissan

$0.00

(0.00%)

, RNLSY

Renault

$0.00

(0.00%)

17:14
12/16/18
12/16
17:14
12/16/18
17:14
Periodicals
Renault seeking Nissan shareholder meeting amid Ghosn crisis, Reuters says »

Renault (RNLSY) requested…

NSANY

Nissan

$0.00

(0.00%)

RNLSY

Renault

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

T

AT&T

$30.24

0.33 (1.10%)

, CMCSA

Comcast

$36.32

-0.43 (-1.17%)

16:48
12/16/18
12/16
16:48
12/16/18
16:48
Hot Stocks
Box Office Battle: 'Spider-Verse' wins weekend with $35M »

Sony's (SNE)…

T

AT&T

$30.24

0.33 (1.10%)

CMCSA

Comcast

$36.32

-0.43 (-1.17%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$51.32

-0.88 (-1.69%)

FOX

21st Century Fox

$48.79

-0.09 (-0.18%)

FOXA

21st Century Fox

$49.06

-0.07 (-0.14%)

LGF.A

Lionsgate

$15.59

-0.16 (-1.02%)

DIS

Disney

$112.21

-1.17 (-1.03%)

VIAB

Viacom

$28.56

-0.31 (-1.07%)

VIA

Viacom

$31.23

-0.4 (-1.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 30

    Jan

  • 20

    Mar

ELGX

Endologix

$0.71

0.0232 (3.39%)

16:17
12/16/18
12/16
16:17
12/16/18
16:17
Conference/Events
Endologix to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRPO

Precipio

$0.19

-0.0111 (-5.63%)

16:11
12/16/18
12/16
16:11
12/16/18
16:11
Conference/Events
Precipio to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSB

Mesabi Trust

$25.15

-1.1 (-4.19%)

16:08
12/16/18
12/16
16:08
12/16/18
16:08
Conference/Events
Mesabi Trust to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLNT

Melinta Therapeutics

$1.19

-0.1 (-7.75%)

16:02
12/16/18
12/16
16:02
12/16/18
16:02
Conference/Events
Melinta Therapeutics to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOM

Exxon Mobil

$75.63

-1.32 (-1.72%)

15:55
12/16/18
12/16
15:55
12/16/18
15:55
Periodicals
Exxon Mobil shareholders call for greenhouse gas reduction targets, Reuters says »

A number of institutional…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANTM

Anthem

$275.59

-4.93 (-1.76%)

, CNC

Centene

$127.55

-5.3 (-3.99%)

13:16
12/16/18
12/16
13:16
12/16/18
13:16
Periodicals
Health stocks preparing for market jolt after Obamacare ruling, Bloomberg says »

U.S. health-care stocks…

ANTM

Anthem

$275.59

-4.93 (-1.76%)

CNC

Centene

$127.55

-5.3 (-3.99%)

CI

Cigna

$205.34

-6.63 (-3.13%)

UNH

UnitedHealth

$265.06

-7.2 (-2.64%)

HUM

Humana

$300.41

-12.09 (-3.87%)

WCG

WellCare

$236.90

-7.44 (-3.04%)

MOH

Molina Healthcare

$131.72

-11.19 (-7.83%)

HNT

Health Net

$0.00

(0.00%)

AET

Aetna

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jan

  • 05

    Feb

  • 19

    Feb

JELD

Jeld-Wen

$14.27

-0.46 (-3.12%)

13:02
12/16/18
12/16
13:02
12/16/18
13:02
Hot Stocks
Jeld-Wen announces final ruling in Steves & Sons litigation, to appeal decision »

Jeld-Wen announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATRA

Atara Biotherapeutics

$41.78

-0.74 (-1.74%)

12:55
12/16/18
12/16
12:55
12/16/18
12:55
Hot Stocks
Atara Biotherapeutics presents positive efficacy, safety results for EBV + LMS »

Atara Biotherapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BGNE

BeiGene

$133.95

2.595 (1.98%)

12:41
12/16/18
12/16
12:41
12/16/18
12:41
Hot Stocks
BeiGene announces updated Phase 1A/1B data on tislelizumab »

BeiGene announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JELD

Jeld-Wen

$14.27

-0.46 (-3.12%)

12:35
12/16/18
12/16
12:35
12/16/18
12:35
Hot Stocks
Jeld-Wen ordered to divest Pennsylvania plant to restore competition »

Federal Judge Robert…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMY

Bristol-Myers

$52.11

-1.54 (-2.87%)

, RHHBY

Roche

$0.00

(0.00%)

04:55
12/16/18
12/16
04:55
12/16/18
04:55
Conference/Events
European Society for Medical Oncology (ESMO) to hold a conference »

ESMO Immuno-Oncology…

BMY

Bristol-Myers

$52.11

-1.54 (-2.87%)

RHHBY

Roche

$0.00

(0.00%)

CELG

Celgene

$68.20

-1.55 (-2.22%)

MRK

Merck

$76.50

-1.94 (-2.47%)

PFE

Pfizer

$43.84

-0.71 (-1.59%)

FLDM

Fluidigm

$7.79

-0.39 (-4.77%)

NEO

NeoGenomics

$13.25

-0.18 (-1.34%)

SGEN

Seattle Genetics

$60.46

-0.5 (-0.82%)

TKPYY

Takeda Pharmaceutical

$0.00

(0.00%)

IMV

IMV Inc

$5.65

-0.14 (-2.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

  • 24

    Dec

  • 29

    Dec

  • 11

    Jan

  • 11

    Jan

  • 24

    Jan

  • 16

    Feb

  • 18

    Mar

  • 20

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.